KOSDAQElectrical Equipment458870

Seers

₩12,630▼ 1.79%2026-11-18 close
Market Cap
₩484.3B
Turnover
₩3.4B
Volume
260K
Shares out.
38.4M
PER
16.0×
PBR
7.9×
EPS
₩877
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Seers: Profitability Tested by a Server Supply Gap

Seers returned to annual profit in 2025, but a server supply shortfall pushed it into an operating loss in Q3 2026. Whether delayed shipments are recognized as revenue in Q4 is the next checkpoint.

  1. 1

    Q3 2026 revenue was KRW 9.78 billion with an operating loss of KRW 1.9 billion. The company disclosed these figures in its preliminary report on November 6, 2026, attributing the drop to delayed server supply for its thynC platform.

  2. 2

    Revenue reached KRW 48.2 billion in 2025 and operating profit reached KRW 16.3 billion, a swing from losses to profit. Q1 2026 was the strongest quarter, with revenue of KRW 32.5 billion and operating profit of KRW 13.9 billion.

  3. 3

    Thync accounts for most revenue, so server procurement is the key variable. The company said it plans to supply about KRW 20 billion of delayed orders in Q4 2026 and recognize them as revenue.

  4. 4

    Samsung Securities cited a target of 30,000 additional beds in 2026 in an April 2026 report, and the company said on November 9, 2026 that it is keeping its annual 30,000-bed order target.

  5. 5

    The company pays no dividend, so dividend-yield comparisons do not apply. Valuation multiples are calculated on the last four quarters of controlling-shareholder net income, which include the Q3 2026 loss.

02

Business structure

Seers runs two main product lines: thynC, an inpatient monitoring platform combining wearable medical devices, AI software and servers, and mobiCARE, a wearable AI arrhythmia diagnostic service.

Samsung Securities estimated 2025 revenue mix at roughly KRW 42.9 billion for thynC and KRW 5.0 billion for mobiCARE in a February 2026 report. In Q3 2026, thynC generated about KRW 8.15 billion and mobiCARE about KRW 1.6 billion according to press coverage of the company's disclosure.

Because thynC makes up most revenue, server procurement is the key variable. Daewoong Pharmaceutical sells thynC through its hospital sales network, while Seers handles supply and technical support. Hospitals order according to their own adoption plans, and Seers supplies the units.

The company says mobiCARE is a service-type model that needs no on-site hospital server and is therefore not affected by server shortages. Samsung Securities said thynC's broad reimbursement coverage and lock-in from installed monitoring are strengths.

In the same report's comparison table, HiCardi+ from Mezoo is a wireless patch type, and AT-Monitoring from Mediana is a wired patient monitoring system. Overseas, a mobiCARE non-reimbursed business with PureHealth, a large Middle East healthcare group, was expected to become visible in the first half of 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15.7B₩6.7B42.7%
2025Q4₩20.4B₩8.7B42.6%
2026Q1₩32.5B₩13.9B42.6%
2026Q2₩28.4B₩12.9B45.6%
2026Q3₩9.8B-₩1.9B−19.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩1.9B-₩9.8B-₩9.9B−520.1%−122.3%111.5%
2024₩8.1B-₩8.7B-₩8.9B−107.2%−41.5%31.2%
2025₩48.2B₩16.3B₩16.1B33.9%40.7%36.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual results moved from losses to profit. Revenue was KRW 1.89 billion in 2023, KRW 8.1 billion in 2024 (up 329.7% year on year) and KRW 48.2 billion in 2025 (up 494.7%), rising two consecutive years from 2024 through 2025. The largest year of 2023 to 2025 was 2025.

Operating loss was KRW 9.8 billion in 2023 and KRW 8.68 billion in 2024, with losses continuing but narrowing, before turning to operating profit of KRW 16.3 billion in 2025.

Controlling-shareholder net income swung from a loss of KRW 8.87 billion in 2024 to a profit of KRW 16.1 billion in 2025, while net income including non-controlling interests was KRW 16 billion. Operating margin moved from -520.1% in 2023 and -107.2% in 2024 to 33.9% in 2025.

Operating cash flow went from KRW -7.9 billion in 2023 and KRW -11.1 billion in 2024 to KRW 2.09 billion in 2025. The debt ratio was 111.5% in 2023, 31.2% in 2024 and 36.8% in 2025.

At the end of 2025, total equity was KRW 39.6 billion, all attributable to controlling shareholders, and total liabilities were KRW 14.6 billion.

Quarterly swings were sharper. Revenue was KRW 15.7 billion in Q3 2025 with operating profit of KRW 6.73 billion, rising to KRW 20.4 billion in Q4 2025 (up 29.7% quarter on quarter) with operating profit of KRW 8.7 billion.

Q1 2026 revenue of KRW 32.5 billion and operating profit of KRW 13.9 billion were described in the press as the company's largest quarter since its founding.

Q2 2026 revenue was KRW 28.4 billion (down 12.8% quarter on quarter) with operating profit of KRW 12.9 billion, and revenue has declined for two consecutive quarters from Q2 to Q3 2026.

Q3 2026 revenue was KRW 9.78 billion (down 65.5% quarter on quarter and 37.9% year on year), and the company posted an operating loss of KRW 1.9 billion. Market expectations for Q3 had been about KRW 33.1 billion in revenue and KRW 14.6 billion in operating profit. Over the last four quarters, controlling-shareholder net income totaled KRW 33.3 billion.

05

Industry analysis

Demand for thynC tracks the spread of bed-side monitoring in hospitals. Seers has completed entry into general hospitals and targets 30,000 additional beds in 2026, according to Samsung Securities in April 2026.

On the supply side, the global AI infrastructure build-out has created imbalances in servers and key components, along with rising prices, which the company says delayed deliveries even under long-term supply contracts.

In response, the company plans to secure at least two quarters of server inventory in advance using recently raised funds. It has also developed its AI engine and software to run on AMD-CPU servers in addition to Intel-based servers.

On the domestic demand side, mobiCARE grew on higher demand for electrocardiogram testing in Korea. In a competitive comparison, Mezoo's HiCardi+ was cited at about 6,000 cumulative beds deployed as of 2025, while Mediana's wearable remote monitoring was described as being at an early entry stage.

Overseas, Mirae Asset Securities said in a 2025 report that the U.S. business was progressing more slowly than expected. The current position combines expanding bed adoption with server supply as the near-term variable.

06

Outlook

The company's near-term goal is a Q4 2026 earnings recovery, and it expects new supply demand on top of delayed shipments in Q4. Server deliveries were completed at the end of October 2026, so the pace of hospital installation and revenue recognition is the key test.

Installation, follow-on orders and revenue recognition steps still remain even after servers arrived. The company is maintaining its annual target of 30,000 beds in orders. For mobiCARE, the company has said Q4 could recover on higher demand for health screening.

Samsung Securities pointed to an FDA 510(k) clearance momentum in mid-2026 as an overseas catalyst. In the Middle East, the non-reimbursed mobiCARE business with PureHealth was cited as a growth factor. On profitability, operating margins stayed high from Q4 2025 through Q2 2026 before the Q3 2026 loss broke that run. The 2026 annual report, the next regular filing, will show where the full-year operating margin settles.

07

Valuation

PER
16.0×
PBR
7.9×
ROE
67.8%
EPS
₩877
BPS
₩1,783
Dividend per share
₩0

The current multiples are calculated on controlling-shareholder net income of KRW 33.3 billion over the last four quarters, which includes the Q3 2026 net loss. Because the company only recently swung from losses to profit, earnings-based multiples can move sharply.

The price-to-book ratio sits in a range with a large premium over net asset value. Total equity of KRW 39.6 billion at the end of 2025 was entirely attributable to controlling shareholders, so book-value comparisons rest on that base. The debt ratio fell to 36.8% in 2025 from 111.5% in 2023.

The company pays no dividend, so dividend-yield comparisons do not apply. Comparisons within the sector are difficult because peers are moving in different earnings directions. The four-quarter total and the multiples will change once Q4 2026 preliminary results and the 2026 annual report are released.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Annual profit and high margin profile

Operating margin moved to 33.9% in 2025 from -107.2% in 2024. Q1 2026 operating profit of KRW 13.9 billion equaled about 85% of full-year 2025 operating profit. Operating cash flow also turned positive, at KRW 2.09 billion in 2025, showing earnings converting into cash.

Bed expansion and service-type model

Samsung Securities cited thynC's broad reimbursement coverage and lock-in from installed monitoring as strengths. The company says it is keeping its 2026 target of 30,000 beds in orders. It describes mobiCARE as a service-type model without on-site hospital servers, which it says is less exposed to server shortages.

Delayed orders and overseas partnerships

The company said it plans to supply about KRW 20 billion of delayed orders in Q4 and recognize them as revenue. In the Middle East, a non-reimbursed mobiCARE business with PureHealth is underway. If the delayed volume is recognized, it could fill the Q3 gap.

09

Bear factors

Dependence on server procurement

Q3 2026 revenue was KRW 9.78 billion, down 37.9% year on year, and operating profit turned to a KRW 1.9 billion loss. thynC revenue of KRW 8.15 billion reflects revenue recognition delayed by server shortages.

The shortfall versus market expectations of about KRW 33.1 billion exposed the fragility of the server procurement structure.

Delivery delays despite long-term contracts

The company said that even with long-term supply contracts, server delivery was delayed. Whether the delayed Q3 volume will show up in Q4 revenue remains to be seen. Installation, follow-on orders and recognition steps leave room for timing lags.

Possible delays in overseas expansion

Mirae Asset Securities noted in a 2025 report that the U.S. business was progressing slower than expected. Overseas revenue is recognized after contracts are signed, so schedule slips delay its contribution. Overseas growth will take time to offset gaps in domestic results.

10

Risk factors

Server supply chain

The global AI infrastructure build-out has created server and component shortages and price increases. The company plans to secure at least two quarters of server inventory with recent funding and diversify suppliers. However, rising server prices could weigh on operating margins if passed into costs.

Revenue concentration and earnings volatility

Most revenue comes from thynC, and sales depend on Daewoong Pharmaceutical's hospital network. Revenue fell from KRW 28.4 billion in Q2 2026 to KRW 9.78 billion in Q3, showing high quarterly volatility. Concentration in one product and one sales channel means a single supply delay can move quarterly results sharply.

Overseas approvals and timing

U.S. FDA clearance and the Middle East non-reimbursed mobiCARE business are timing variables that could slip. Mirae Asset Securities flagged in a 2025 report that the U.S. business was running behind schedule. Overseas revenue is recognized only after contracts, so delays push back growth contributions.

11

What to watch next

  1. December 2026

    Whether about KRW 20 billion of delayed orders scheduled for Q4 supply is recognized as revenue. This is the first indicator of whether the Q3 revenue gap is filled.

  2. End of December 2026

    Whether the annual target of 30,000 beds in orders is met. Cumulative thynC orders and installations against the target are the measure.

  3. Early 2027

    Q4 2026 earnings release. Check whether the server inventory strategy lifts operating margin and how Q4 revenue compares with Q3.

  4. Around March 2027

    Filing of the 2026 annual report. Reconcile full-year figures with quarterly totals and check where operating margin settles from 33.9% in 2025.

12

Overall view

Seers swung from an operating loss in 2023 to operating profit of KRW 16.3 billion in 2025, and posted revenue of KRW 32.5 billion and operating profit of KRW 13.9 billion in Q1 2026.

Q3 2026 then reversed sharply, with revenue of KRW 9.78 billion and an operating loss of KRW 1.9 billion, which the company attributed to thynC server shortages. The company has said it will supply about KRW 20 billion of delayed orders in Q4 and maintain its 30,000-bed annual order target.

Strengths include the annual profit base, high operating margins and the service-type mobiCARE model. Weaknesses include dependence on server procurement, revenue concentration and possible overseas delays.

Controlling-shareholder net income over the last four quarters totals KRW 33.3 billion, and valuation reads depend on that total. The next checkpoints are the recognition of delayed orders in December 2026, the Q4 2026 results in early 2027, and the 2026 annual report around March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. file.alphasquare.co.kr
  3. samsungpop.com
  4. securities.miraeasset.com
  5. pharm.edaily.co.kr
  6. sedaily.com
  7. vegannews.co.kr
  8. m.thinkpool.com
  9. m.thinkpool.com
  10. samsungpop.com
  11. biz.newdaily.co.kr
  12. sentv.co.kr
  13. sentv.co.kr
  14. m.thinkpool.com
  15. news1.kr
  16. etoday.co.kr
  17. supple.kr
  18. newsis.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis